The Ashton at Anderson Investor Presentation Fourth Quarter and Full Year 2025 March 11, 2026 SNDA NYSE Listed Forward-Looking Statements Explanatory Note As further described in the Company's Current Report on Form 8-K filed with the SEC on March 11, 2026, the Company completed its previously announced acquisition of CNL Healthcare Properties, Inc. ("CHP") through a series of steps ending with a forward merger of CHP with and into a subsidiary of the Company (the "CHP merger" or "merger"), with such subsid ...

Cytokinetics FY Conference Summary Company Overview - **Company**: Cytokinetics (NasdaqGS:CYTK) - **Focus**: Development and commercialization of cardiac myosin inhibitors, specifically MYQORZO (aficamten) Key Industry Insights - **Launch of MYQORZO**: - Launched in late January 2026, with early metrics showing over 90% awareness among high-volume prescribers of CAMZYOS, the existing cardiac myosin inhibitor [4][5] - Over 700 cardiologists have completed the REMS program and are already dispensing MYQORZO [5] - Initial prescriptions are coming from both established prescribers and new prescribers, indicating strong interest [5] Core Points and Arguments - **Market Awareness and Adoption**: - High awareness of MYQORZO among targeted cardiologists suggests a strong potential for adoption [4] - Early signs of interest include requests for information on switching patients from CAMZYOS to MYQORZO [5][7] - **Differentiation from Competitors**: - MYQORZO offers a different physician and patient experience, particularly in terms of speed of onset and dosing flexibility [16][20] - The promotion strategy focuses on safety, efficacy, and a unique experience for both physicians and patients [20] - **Financial Strategy**: - The company has strengthened its balance sheet through strategic partnerships and successful financing efforts, allowing for investment in both U.S. and European launches [26] - Plans to launch in Germany in Q2 2026, with ongoing investments in understanding market dynamics in Europe [25][26] Pipeline Developments - **ACACIA-HCM Study**: - Represents an opportunity for MYQORZO to demonstrate clinical safety and efficacy in non-obstructive hypertrophic cardiomyopathy (NHCM) [29] - The study is designed to address dosing challenges specific to NHCM, with a focus on maximum tolerated doses [32][34] - Positive phase 2 data has been observed, with improvements in biomarkers and patient-reported outcomes [35] - **Future Pipeline**: - Omecamtiv mecarbil is in a confirmatory phase 3 study for advanced heart failure, with a large patient population at high risk of mortality [52] - Ulacamten is being studied in heart failure with preserved ejection fraction (HFpEF), indicating a robust pipeline focused on specialty cardiology [53][54] Strategic Vision - **Independent Operations in Europe**: - Cytokinetics aims to operate independently in Europe, believing it can achieve profitability through strategic pricing and market understanding [48][49] - The company is focused on building a specialty cardiology franchise, leveraging its expertise and pipeline to create a valuable enterprise [49][50] Additional Considerations - **Potential Halo Effect**: - Success in the ACACIA-HCM study could positively influence MYQORZO sales in obstructive hypertrophic cardiomyopathy (OHCM) by reinforcing clinical efficacy [42][46] - **Long-term Goals**: - The company is committed to growing its top line responsibly while fulfilling fiduciary obligations to shareholders [58] This summary encapsulates the key points discussed during the Cytokinetics FY Conference, highlighting the company's strategic direction, market positioning, and pipeline developments.

Summary of Nasus Pharma Conference Call Company Overview - **Company Name**: Nasus Pharma - **Ticker Symbol**: NSRX (New York Stock Exchange) - **Industry**: Pharmaceutical - **Core Technology**: Proprietary powder technology designed to enhance intranasal absorption of various molecules, with a key focus on epinephrine intranasal powder for anaphylaxis [2][23] Key Product and Market Insights - **Lead Product**: NS002, an intranasal epinephrine powder for anaphylaxis, positioned as an alternative to EpiPen - **Market Size**: Current market for anaphylaxis treatment is approximately $2.5 billion, expected to grow to $4-$5 billion due to rising allergy incidences [9][31] - **Patient Demographics**: In the U.S., around 20 million patients are at risk for anaphylaxis, with only about 7 million having a prescription for an epinephrine auto-injector [9][32] - **Market Opportunity**: Significant growth potential for needle-free products, targeting patients who are needle-phobic or currently without a prescription [10][33] Product Advantages - **Performance**: NS002 demonstrated superior pharmacokinetic properties compared to EpiPen, including: - Faster absorption (shorter Tmax) - Higher maximum concentration (Cmax) - Achieving therapeutic thresholds more rapidly (91% of subjects reached therapeutic threshold within 5 minutes) [15][19][18] - **Formulation Benefits**: - Needle-free, compact design enhances usability - Longer shelf life due to powder formulation, avoiding the need for annual replacement [9][22] - **Clinical Study Results**: Recent studies validated the advantages of the powder technology, showing faster and higher absorption rates compared to traditional liquid formulations [14][15][17] Pipeline Development - **Upcoming Products**: - Ondansetron (Zofran) for chemotherapy-induced nausea and vomiting, transitioning from oral to intranasal formulation - Two undisclosed molecules targeting large market opportunities in metabolic and cardiovascular spaces, expected to enter clinical development in 2026 [3][36][37] - **Milestones**: - IND submission planned for Q3 2026 - Initiation of pivotal phase 3 study in Q4 2026 - Top-line data from pivotal study expected by Q1 2027, with NDA submission targeted for mid-2027 [38][39] Competitive Landscape - **Comparison with Competitors**: - Nasus Pharma's product is positioned as superior to competitors like Orexo's OX640, which requires additional additives that reduce the amount of active ingredient delivered [27][31] - **Market Research Validation**: Allergists prioritize speed of onset and performance, which aligns with the advantages of Nasus's product [13][12] Intellectual Property - **IP Protection**: Strong intellectual property covering both the powder technology and product formulations, providing a competitive edge in the market [22][30] Conclusion - Nasus Pharma is strategically positioned in the growing anaphylaxis treatment market with its innovative needle-free epinephrine product, backed by robust clinical data and a promising pipeline of additional therapeutic options. The company aims to leverage its proprietary technology to capture significant market share as the industry shifts towards needle-free solutions.

SeaStar Medical Conference Summary Company Overview - **Company Name**: SeaStar Medical - **Ticker Symbol**: ICU (NasdaqCM) - **Focus**: Treating hyperinflammation in critically ill patients, particularly those facing organ failure or life-threatening conditions such as Acute Kidney Injury and cardiovascular diseases [4][5] Core Products and Pipeline - **FDA-Approved Product**: QUELIMMUNE for Children - **Pipeline**: Includes the Selective Cytopheretic Device (SCD), which has received Breakthrough Device designation from the FDA for various applications [4][5] - **Market Opportunity**: Approximately 1 million patients annually could benefit from SCD, with significant revenue potential from capturing even a modest market share [5] Clinical Data and Efficacy - **SCD Mechanism**: A therapeutic medical device that neutralizes overactive immune cells, reducing mortality and dialysis dependency [6][10] - **Pediatric Study Results**: - Registration study with 22 patients showed a 50% improvement in survival rates (from 50% to 77%) and no long-term dialysis patients at Day 60 [14][15] - SAVE Registry confirmed similar results in real-world settings, with a reduction in mortality and dialysis dependency [15][16] - **Regulatory Updates**: FDA approved a reduction in the number of patients required for the SAVE Registry from 300 to 50, with 50 patients now enrolled [17][18] Commercial Strategy - **Customer Base Growth**: - End of 2024: 2 active customers - End of 2025: 10 customers - Goal for 2026: Double the customer base [22] - **Target Market**: Focus on the top 50 children's hospitals in the U.S., which represent half of the eligible patient population [22][23] Ongoing Trials - **NEUTRALIZE-AKI Trial**: - A randomized controlled study with 339 patients, currently 40% enrolled [25] - Primary endpoints include mortality rates and dialysis dependency [26] - Expected to complete enrollment by the end of 2026, with top-line data available in the first half of 2027 [29] Competitive Advantage - **Comparison with Standard Care**: Current standard of care (Continuous Renal Replacement Therapy) has a 50% mortality rate and is not disease-modifying. SCD aims to improve outcomes significantly [34] - **Economic Benefits**: QUELIMMUNE can reduce ICU length of stay and overall healthcare costs, potentially saving hospitals $40,000 to $50,000 per patient [35] Future Opportunities - **Cardiorenal Syndrome**: SCD may help patients bridge to LVAD or transplant by reducing inflammation [37] - **Regulatory Pathways**: Plans to submit modular pieces for PMA to expedite the approval process [30][31] Financial Overview - **Revenue Projections**: Expected to generate over $1 million in revenue for QUELIMMUNE in 2025, with a goal to double that in 2026 [40] - **Cash Position**: As of November, approximately $13.5 million in cash, with a monthly burn rate of $1 million to $1.3 million [41] Key Milestones for Investors - Completion of NEUTRALIZE-AKI enrollment - Doubling the customer base for QUELIMMUNE - Progress in NEUTRALIZE-CRS study and potential regulatory applications [50][51]

Summary of Xeris Biopharma FY Conference Call (March 11, 2026) Company Overview - **Company**: Xeris Biopharma (NasdaqGS:XERS) - **CEO**: John Shannon - **CFO**: Steve Pieper - **Business Model**: Fast-growing commercial biopharma company with three commercial products: - **Gvoke**: Rescue pen for hypoglycemia - **KEVEYIS**: Treatment for primary periodic paralysis - **Recorlev**: Treatment for hypercortisolemia and Cushing's syndrome, identified as the primary growth driver - **Pipeline**: XP-8121, a once-weekly SubQ levothyroxine for hypothyroidism, is phase 3-ready and expected to start trials in 2026 [5][6][8] Financial Performance - **2025 Revenue**: $292 million, exceeding expectations with a 44% growth year-over-year [8] - **Adjusted EBITDA**: $60 million, marking a transition to positive EBITDA [8] - **Net Income**: Achieved for the full year, indicating the ability to self-fund strategy and pipeline [8] Product Performance Recorlev - **Growth**: Over 100% growth for the past two years, with significant acceleration noted in late 2024 [10][14] - **Market Dynamics**: Increased patient screening and diagnosis in hypercortisolemia led to a larger patient base [14] - **Sales Organization Expansion**: Increased from 28 to 42 sales personnel to capture market opportunities [14] - **Future Guidance**: Majority of growth expected in 2026 will come from Recorlev, with confidence in meeting or exceeding guidance [28][30] Gvoke - **Steady Growth**: Consistent growth since launch, targeting insulin users who need protection from hypoglycemia [20] - **Market Penetration**: Approximately 15 million potential users, with only 1 million currently using Gvoke [20] - **Revenue Growth Expectation**: Anticipated growth in the high single digits to low double digits for the foreseeable future [21] KEVEYIS - **Resilience**: Despite generic competition, KEVEYIS returned to growth in Q4 2025 after initial declines [24] - **Patient Support Services**: Additional services around the product have contributed to its resilience [25] Competitive Landscape - **Market Dynamics**: Increased competition in the hypercortisolemia space is viewed positively, as it helps identify and treat more patients [34] - **RECORLEV Differentiation**: Unique mechanism of action that normalizes cortisol levels, distinguishing it from competitors that only block cortisol at the receptor level [42][43] Future Outlook - **Peak Sales Target for Recorlev**: $1 billion by 2035, with ongoing investments required to support growth [45][46] - **XP-8121 Potential**: Positioned as a blockbuster with a significant unmet medical need, targeting 3-5 million patients who struggle with GI absorption issues [81] - **Balance Sheet Strength**: Ended the year with over $110 million in cash, allowing for continued investment in key products [84] Conclusion - **Market Positioning**: Xeris Biopharma is focused on executing its strategy and believes that continued performance will lead to rational market movements and stock appreciation [86]

GSK FY Conference Summary Company Overview - **Company**: GSK (NYSE:GSK) - **Date**: March 11, 2026 - **Key Speaker**: David Redfern, Chief Strategy Officer and Chairman of ViiV Core Industry Insights Strategic Direction - GSK is focused on maintaining its strategic direction under new CEO Luke Miels, emphasizing execution, growth, and simplification of the business [4][5] - Key therapy areas include respiratory, inflammation, immunology, oncology, infectious diseases, and vaccines [4][5] Business Development and M&A - GSK has been active in M&A, closing deals with RAPT for food allergy treatment and Thirty-Five Pharma for pulmonary hypertension [7][10] - The RAPT asset is seen as an improved version of Xolair, targeting a significant market of 17 million people in the U.S. [7][8] - The Thirty-Five Pharma deal focuses on a drug for pulmonary hypertension, which is in early clinical stages [10] Pipeline Execution - GSK is concentrating on mid to late-stage assets that will drive growth into the 2030s, with a focus on optimizing R&D processes [6][12] Product Launches and Market Opportunities Exdensur (IL-5 for Severe Asthma) - Exdensur offers a six-month dosing regimen, which is expected to increase biologic penetration in the under-treated severe asthma market [22][24] - The product is anticipated to face standard insurance coverage processes, with no unusual challenges expected [25][26] Nucala (IL-5 for COPD) - Nucala has shown a 35% reduction in exacerbations leading to hospitalizations, addressing a significant unmet medical need in COPD [28] - GSK is exploring additional mechanisms and combinations for COPD treatment, including trials for different severity levels [30] Blenrep (BCMA Agent for Hematological Cancers) - Blenrep has shown promising efficacy, with a significant reduction in risk of death compared to standard care [33] - The launch strategy includes careful training for healthcare providers to ensure positive patient experiences [35][36] HIV Pipeline Developments Long-Acting Treatments - GSK is advancing its six-month treatment options for HIV, with promising data on third-generation integrase and capsid inhibitors [46][47] - The company is focused on developing a best-in-class six-month treatment regimen, with plans for further clinical testing [48] Competitive Landscape - GSK acknowledges the growing PrEP market and the potential impact of competitors like Gilead, but remains confident in the growth of its long-acting product Apretude [58] Additional Insights - GSK is strategically diversifying its portfolio beyond infectious diseases and oncology, focusing on respiratory and inflammation areas [11][12] - The company is leveraging AI for patient stratification in COPD, indicating a sophisticated approach to clinical development [30] Conclusion GSK is positioning itself for future growth through strategic M&A, a robust pipeline focused on mid to late-stage assets, and innovative product launches across various therapeutic areas. The emphasis on execution and simplification under the new CEO is expected to drive the company's performance into the next decade.

Summary of Xencor Fireside Chat Company Overview - **Xencor** is a biotechnology company specializing in protein engineering technology, particularly in creating antibodies with best-in-class properties. The company has established a broad pipeline in oncology and autoimmune diseases, focusing on proprietary drug development, especially in solid tumors and T-cell engagers [2][3]. Key Milestones and Focus Areas - Xencor aims to define dosing regimens and efficacy profiles for its lead solid tumor T-cell engagers, **XmAb819** and **XmAb541**, with pivotal trials expected to initiate in 2027 [3][6]. - The company is also focused on developing a **TL1A bispecific** and long-acting monospecific antibody, with key readouts anticipated to enhance value creation in late-phase development [5]. XmAb819 Development Insights - **XmAb819** targets ENPP3-expressing tumor cells while sparing normal tissues, showing a promising 25% response rate in heavily pretreated renal cell carcinoma patients [7][12]. - The design of XmAb819 aims to avoid impacting healthy tissues, with early clinical data indicating excellent tolerability after the initial priming doses [7][11]. - The company is exploring the potential to move XmAb819 into earlier lines of therapy, leveraging its novel mechanism and high ENPP3 expression in clear cell renal cell carcinoma [13][19]. Clinical Development Strategy - Xencor is conducting a sub-study to evaluate XmAb819's monotherapy potential in TKI-naive patients, which could significantly impact the treatment landscape [22]. - The company is also assessing combination therapy opportunities, particularly with PD-1 inhibitors and HIF-2 alpha, to address the unmet needs in renal cell carcinoma [31][32]. XmAb541 and Other Oncology Programs - Initial data from the **XmAb541** program in ovarian and germ cell tumors is being evaluated to determine its potential as a significant opportunity or a niche product [43][51]. - The company is enrolling patients across various tumor types, including papillary renal cell and colorectal cancer, to establish a robust data set for future strategic decisions [57]. Immunology Focus - Xencor's **TL1A** program, particularly **XmAb942**, is designed to have a long half-life and durable suppression of TL1A levels, with a phase 2b global study planned to establish the phase 3 dose [61][62]. - The company aims to position its TL1A program as best-in-class by focusing on efficacy, durability, and dosing convenience, with a target of Q12 week dosing in maintenance [73]. Market Opportunities and Strategic Considerations - Xencor anticipates significant market opportunities in both oncology and immunology, with the potential to capture substantial patient populations [29][82]. - The company is considering partnerships but currently views its assets as capable of being developed independently [60]. Conclusion - Xencor is strategically positioned in the biotechnology sector with a focus on innovative therapies for oncology and immunology. The company is actively advancing its clinical programs and exploring various avenues for maximizing the utility of its drug candidates in the market [1][84].

Affirm Conference Call Summary Company Overview - **Company**: Affirm (NasdaqGS:AFRM) - **Industry**: Buy Now, Pay Later (BNPL) and e-commerce financing Key Accomplishments and Financial Performance - **Growth Metrics**: - GMV (Gross Merchandise Volume) grew by **39%** over the last 12 months [3] - Recent quarter reported **30%** adjusted operating income [4] - Fiscal second quarter saw **36%** GMV growth, **23%** active consumer growth, and **29%** RLTC (Revenue per Loan Transaction) growth [20] - GAAP operating margins expanded to nearly **11%** [20] - **Affirm Card Performance**: - Affirm Card accounted for **16%** of GMV in the last quarter, with **14%** of users utilizing the card [5] - User adoption of Affirm Card doubled year-over-year [23] Merchant Partnerships - Renewed partnership with **Amazon** for five years and with **Expedia** [6][21] - New partnerships include **Intuit**, **Lowe's**, and **ServiceTitan** [6] Consumer Network and Value Proposition - Affirm has nearly **26 million** active consumers, enhancing its value proposition to merchants [7] - Two-thirds of volume comes from monthly interest-bearing loans, allowing flexibility in monetization [13] Guidance and Market Conditions - Fiscal year guidance projects **32.5%** GMV growth and RLTC just over **4%** [31] - Credit metrics remain stable, with **96%** of transactions from repeat borrowers [44] - No significant changes in competitive intensity noted [72] Profitability and Investment Strategy - Affirm views growth and profitability as complementary rather than trade-offs [55] - Plans for continued margin expansion and investment in AI tools to enhance efficiency [61][62] International Expansion - Ongoing optimization in the UK with Shopify and new merchant wins like **Virgin Media O2** and **Wayfair** [94][96] Regulatory Landscape - Proposed legislation in New York regarding BNPL is not seen as a headwind for Affirm [129] Future Opportunities - Exploring vertical diversification, particularly in services through partnerships with **ServiceTitan** and **Intuit** [102] - Submitted application for a bank subsidiary, expected to diversify loan origination and funding channels [107][110] Conclusion - Affirm is experiencing strong growth and profitability, with a solid operational plan and positive market conditions. The company is focused on expanding its consumer base, enhancing merchant partnerships, and exploring new verticals while maintaining a stable credit posture.

Vertex Pharmaceuticals FY Conference Summary Company Overview - **Company**: Vertex Pharmaceuticals (NasdaqGS: VRTX) - **Industry**: Biotechnology, focusing on cystic fibrosis and expanding into renal and pain management therapies Key Points Strategic Diversification - Vertex has transitioned from a cystic fibrosis-focused company to a more diversified biotech firm, aiming to broaden its revenue base and patient demographics [2][3] - The company has launched ALYFTREK, its fifth commercialized medicine, and is developing a next-gen 3.0 family of therapies [2] Revenue Projections - Vertex expects combined revenue from CASGEVY (for sickle cell disease and beta thalassemia) and Journavx (for acute pain) to exceed $500 million in 2026 [3] - Journavx is projected to triple the number of prescriptions in 2026 compared to 2025, with revenue growth expected to outpace prescription growth [3] Renal Franchise Development - Vertex aims to establish a renal franchise comparable in size to its cystic fibrosis business, with three ongoing phase 3 programs and a phase 2 study for autosomal dominant polycystic kidney disease [4] - The company is committed to R&D in serious diseases with validated markers and efficient clinical pathways [5] Povetacicept Data Highlights - Povetacicept shows a 52% reduction in UPCR at 36 weeks, with significant secondary endpoint results: 77% reduction in Gd-IgA1 and 85% resolution of hematuria [7][8] - 42% of patients achieved KDIGO recommended guidelines of UPCR less than 0.5 grams per gram, indicating strong efficacy in a real-world patient population [9] Safety Profile - The safety profile of povetacicept is favorable, with most adverse events being mild or moderate and no serious adverse events related to the drug [19] - No discontinuations due to infections were reported, and common adverse events included upper respiratory tract infections and injection site reactions [19] Future Studies and Indications - Vertex is conducting phase 2/3 studies for primary membranous nephropathy and plans to initiate a phase 2 study for myasthenia gravis in the first half of the year [23][24] - The company sees potential for povetacicept in multiple conditions, with ongoing discussions about commercial opportunities in nephrology [26] Cystic Fibrosis Business Update - ALYFTREK is expected to see continued growth, with a focus on younger patients and rare mutations, particularly in Europe [35] - The company reported that 30% of patients aged 12+ and over 60% of patients aged 2-5 are achieving diagnostic levels, indicating strong treatment efficacy [37] Journavx Commercial Strategy - Vertex is doubling its sales force from 150 to 300 reps to enhance physician access and drive adoption of Journavx [44] - The company is increasing marketing investments, including direct-to-consumer advertising, to boost awareness and uptake [44] Upcoming Trials - Vertex is conducting two phase 3 trials for diabetic peripheral neuropathy, with enrollment expected to complete by year-end, setting the stage for results in 2027 [50] Conclusion - Vertex Pharmaceuticals is strategically diversifying its portfolio beyond cystic fibrosis, with promising developments in renal therapies and pain management. The company is focused on maintaining a strong safety profile while driving revenue growth through innovative therapies and expanding its commercial capabilities.

Summary of Evolus Conference Call Company Overview - **Company**: Evolus - **Industry**: Aesthetic medicine, specifically focusing on toxins and fillers Key Points Market Dynamics - The toxin market is showing signs of recovery after a challenging period, with improvements noted in Q4 of the previous year and continuing into Q1 of the current year [4][8] - Historically, the toxin market has only experienced three significant downturns: the 2008-2009 recession, COVID-19 shutdowns, and the recent slowdown attributed to middle-class consumers reducing spending due to rising costs [4][5] - The current guidance suggests low single-digit growth for the toxin market, with expectations of mid-single-digit growth by 2027-2028 [9] Consumer Behavior - The slowdown in the toxin market was primarily driven by middle-class consumers stretching intervals between treatments, seeking to maximize their spending [5][7] - Consumer confidence is beginning to improve, leading to increased clinic activity and a slight uptick in the Consumer Confidence Index [7][8] Filler Market Insights - The filler market is recovering at a slower pace compared to the toxin market, impacted by negative perceptions around overfilled faces [14][17] - Clinics are shifting their messaging to promote hyaluronic acid (HA) as a natural ingredient rather than a filler, which is expected to improve consumer sentiment [16][17] Product Differentiation - Evolus's filler product, Evolysse, is performing well despite a challenging market, with clinics appreciating its efficiency and natural look [37][39] - The company has trained over 12,000 injectors to enhance confidence in using Evolysse, which is crucial for its adoption [39] Financial Guidance - For 2026, Evolus projects revenues between $327 million and $337 million, representing a 10%-13% year-over-year growth [80] - By 2028, the revenue is expected to reach between $450 million and $500 million, with adjusted EBITDA margins of 13%-15% [82] - International revenue is anticipated to grow from 8% in 2025 to 15% by 2028, driven by expanding market presence in Europe and new product launches [83][118] Strategic Initiatives - Evolus is focusing on bundling its products to enhance market share and customer loyalty, with a pilot program showing positive results [40][41] - The company is also investing in co-branded media to support clinics, maintaining an annual advertising spend of $9 million to $12 million [170] Customer Loyalty Program - Evolus has developed a consumer loyalty program with over 1.4 million active participants, which incentivizes repeat visits to clinics [164][200] - The program is designed to be frictionless and automated, enhancing customer engagement and clinic partnerships [208][210] Future Outlook - The upcoming launch of the Sculpt product is expected to be a significant revenue driver, potentially accounting for 40% of the filler line's revenue [102][106] - Evolus aims to continue expanding its product portfolio and market presence, with a focus on both U.S. and international markets [121][122] Additional Insights - The international market for toxins and fillers represents a $2 billion opportunity, with Evolus currently holding a low single-digit market share [134][140] - The company is actively monitoring market trends and consumer behavior to adapt its strategies accordingly [152][153]